Sector: HealthcareIndustry: Drug Manufacturers - GeneralCIK: 0000059478
Market Cap795.68 Bn
P/E38.57
P/S12.21
Div. Yield0.01
ROIC (Qtr)0.52
Total Debt (Qtr)42.50 Bn
Revenue Growth (1y) (Qtr)42.55
Add ratio to table...
About
Eli Lilly and Company, commonly referred to as Lilly, is a prominent player in the pharmaceutical industry, operating under the ticker symbol LLY. The company's operations are centered on the discovery, development, manufacturing, and marketing of human pharmaceutical products, with a global footprint spanning approximately 105 countries.
Lilly's primary business activities revolve around the development and commercialization of innovative medicines that target significant unmet medical needs. The company's product portfolio is diverse, encompassing...
Eli Lilly and Company, commonly referred to as Lilly, is a prominent player in the pharmaceutical industry, operating under the ticker symbol LLY. The company's operations are centered on the discovery, development, manufacturing, and marketing of human pharmaceutical products, with a global footprint spanning approximately 105 countries.
Lilly's primary business activities revolve around the development and commercialization of innovative medicines that target significant unmet medical needs. The company's product portfolio is diverse, encompassing several therapeutic areas such as diabetes, obesity, and cardiometabolic products; oncology products; immunology products; and neuroscience products. These products are marketed and sold in various regions, including the United States, where they are distributed through a network of sales representatives, wholesalers, and pharmacies. In international markets, Lilly promotes its products to healthcare providers through sales representatives and other channels.
The revenue for Lilly is primarily generated through the sales of its products, which are categorized into several therapeutic areas. In the diabetes, obesity, and cardiometabolic segment, the company offers products such as Jardiance, Mounjaro, and Trulicity. In the oncology segment, Lilly's offerings include Cyramza and Verzenio, while the immunology segment boasts products like baricitinib. The neuroscience segment includes solriamfetol and galcanezumab among its products. These products are designed to cater to specific medical needs and are marketed to healthcare providers, wholesalers, and pharmacies.
In the highly competitive pharmaceutical industry, Lilly competes with other companies, including those that offer generic and biosimilar products. The company's competitive advantage stems from factors such as the effectiveness, safety, and ease of use of its products, regulatory approvals, marketing effectiveness, and research and development of new products. Lilly's intellectual property portfolio, which includes patents, trademarks, and other intellectual property rights, is critical to its business and provides protection for its products and innovations.
The company's customers include healthcare providers, wholesalers, and pharmacies, and Lilly has a significant presence in over 105 countries worldwide. The company's products are sold in many countries, including the US, Europe, Japan, and China.
In terms of brand names, Lilly's offerings include Jardiance, Mounjaro, Trulicity, Cyramza, Verzenio, baricitinib, solriamfetol, and galcanezumab, among others. These products are designed to address specific medical needs and are marketed to healthcare providers, wholesalers, and pharmacies.
Eli Lilly’s latest earnings demonstrate a rare convergence of revenue growth, margin stability, and market‑share expansion, all of which point to a robust growth trajectory that the market has yet to fully price in. The company posted a 45% rise in full‑year revenue, largely driven by the explosive volume gains of Mounjaro and Zepbound, and an 86% increase in EPS, underscoring an efficient capital‑allocation strategy that boosts shareholder value while still investing heavily in R&D. Even as realized US prices fell 7% year‑over‑year, the company’s ability to offset that loss through volume growth in both diabetes and obesity markets signals a resilient pricing power that can sustain the 25% top‑line lift outlined in its 2026 guidance. This volume‑driven momentum is especially compelling given the company’s high market‑share targets—over 55% in new type‑two diabetes prescriptions and 70% in new branded obesity prescriptions—hinting at a durable advantage in these fast‑growing therapeutic areas.
The upcoming Medicare coverage for obesity therapies, slated to take effect no later than July 1, 2026, is a hidden catalyst that can open a 40 million‑patient pool to Lilly’s high‑efficacy drugs while keeping out‑of‑pocket costs low at $50. By leveraging its direct‑to‑patient platform, which already engaged one million US patients, Lilly is positioned to capture early adopters and create brand loyalty in a consumer‑driven market segment that is increasingly moving away from insurer‑dependent models. The company’s strategic pricing of Zepbound self‑pay vials, which now comprise nearly one‑third of all new obesity starts, further demonstrates its ability to tailor product offerings to consumer price sensitivities, thereby unlocking volume that traditional payer models may miss. With Medicare’s expansion, Lilly can now deliver its proven GLP‑1s to a broader demographic, ensuring that the 2026 revenue outlook remains realistic even under the anticipated price drag.
Lilly’s R&D engine has entered a phase of unprecedented breadth, featuring 36 active Phase III programs, 14 newly initiated studies, and breakthrough therapy designation for sofetibart. The company’s pipeline now spans cardiometabolic, oncology, immunology, and neuroscience, reducing dependence on any single therapeutic area. In addition to conventional discovery, Lilly has entered an AI‑powered co‑innovation lab with NVIDIA, a partnership that promises to accelerate early‑stage candidate identification and de‑risk clinical development timelines. The recently announced collaboration with Scribe Therapeutics, which has reached a second success milestone in CRISPR‑based gene editing, adds a potential high‑margin, transformative product line that could diversify Lilly’s revenue sources beyond prescription drugs. This diversified pipeline not only spreads risk but also creates a series of future blockbuster candidates that can sustain the company’s growth trajectory in the post‑inflationary era.
A cornerstone of Lilly’s supply‑chain resilience is its aggressive manufacturing expansion, having invested over $55 billion since 2020 and opened new facilities in Wisconsin and North Carolina. The company now produces 1.8 times the number of incretin doses it did in 2024, a capacity that comfortably supports its rapid volume growth in Mounjaro and Zepbound. The decision to build a manufacturing hub in India further strengthens Lilly’s global supply footprint, allowing it to tap a robust contract‑manufacturing ecosystem and reduce logistics bottlenecks, especially for its emerging weight‑loss portfolio. This infrastructure underpins the company’s ability to meet demand spikes, maintain product availability, and potentially reduce unit production costs—factors that can be passed on to customers and help sustain pricing flexibility.
Lilly’s financial discipline, evidenced by an 83.2% gross margin and a 47.2% non‑GAAP performance margin, provides a robust cushion for the company to continue rewarding shareholders. The firm paid $1.3 billion in dividends and repurchased $1.5 billion of shares in 2025, signaling confidence in its cash‑flow generation while also signaling a commitment to returning value to shareholders. Coupled with a strong balance sheet, this financial flexibility allows Lilly to invest aggressively in its pipeline and marketing without jeopardizing liquidity. Moreover, the company’s ability to maintain high margins even as it increases R&D and marketing spend demonstrates effective cost control, which is vital in an industry increasingly beset by pricing headwinds.
Eli Lilly’s latest earnings demonstrate a rare convergence of revenue growth, margin stability, and market‑share expansion, all of which point to a robust growth trajectory that the market has yet to fully price in. The company posted a 45% rise in full‑year revenue, largely driven by the explosive volume gains of Mounjaro and Zepbound, and an 86% increase in EPS, underscoring an efficient capital‑allocation strategy that boosts shareholder value while still investing heavily in R&D. Even as realized US prices fell 7% year‑over‑year, the company’s ability to offset that loss through volume growth in both diabetes and obesity markets signals a resilient pricing power that can sustain the 25% top‑line lift outlined in its 2026 guidance. This volume‑driven momentum is especially compelling given the company’s high market‑share targets—over 55% in new type‑two diabetes prescriptions and 70% in new branded obesity prescriptions—hinting at a durable advantage in these fast‑growing therapeutic areas.
The upcoming Medicare coverage for obesity therapies, slated to take effect no later than July 1, 2026, is a hidden catalyst that can open a 40 million‑patient pool to Lilly’s high‑efficacy drugs while keeping out‑of‑pocket costs low at $50. By leveraging its direct‑to‑patient platform, which already engaged one million US patients, Lilly is positioned to capture early adopters and create brand loyalty in a consumer‑driven market segment that is increasingly moving away from insurer‑dependent models. The company’s strategic pricing of Zepbound self‑pay vials, which now comprise nearly one‑third of all new obesity starts, further demonstrates its ability to tailor product offerings to consumer price sensitivities, thereby unlocking volume that traditional payer models may miss. With Medicare’s expansion, Lilly can now deliver its proven GLP‑1s to a broader demographic, ensuring that the 2026 revenue outlook remains realistic even under the anticipated price drag.
Lilly’s R&D engine has entered a phase of unprecedented breadth, featuring 36 active Phase III programs, 14 newly initiated studies, and breakthrough therapy designation for sofetibart. The company’s pipeline now spans cardiometabolic, oncology, immunology, and neuroscience, reducing dependence on any single therapeutic area. In addition to conventional discovery, Lilly has entered an AI‑powered co‑innovation lab with NVIDIA, a partnership that promises to accelerate early‑stage candidate identification and de‑risk clinical development timelines. The recently announced collaboration with Scribe Therapeutics, which has reached a second success milestone in CRISPR‑based gene editing, adds a potential high‑margin, transformative product line that could diversify Lilly’s revenue sources beyond prescription drugs. This diversified pipeline not only spreads risk but also creates a series of future blockbuster candidates that can sustain the company’s growth trajectory in the post‑inflationary era.
A cornerstone of Lilly’s supply‑chain resilience is its aggressive manufacturing expansion, having invested over $55 billion since 2020 and opened new facilities in Wisconsin and North Carolina. The company now produces 1.8 times the number of incretin doses it did in 2024, a capacity that comfortably supports its rapid volume growth in Mounjaro and Zepbound. The decision to build a manufacturing hub in India further strengthens Lilly’s global supply footprint, allowing it to tap a robust contract‑manufacturing ecosystem and reduce logistics bottlenecks, especially for its emerging weight‑loss portfolio. This infrastructure underpins the company’s ability to meet demand spikes, maintain product availability, and potentially reduce unit production costs—factors that can be passed on to customers and help sustain pricing flexibility.
Lilly’s financial discipline, evidenced by an 83.2% gross margin and a 47.2% non‑GAAP performance margin, provides a robust cushion for the company to continue rewarding shareholders. The firm paid $1.3 billion in dividends and repurchased $1.5 billion of shares in 2025, signaling confidence in its cash‑flow generation while also signaling a commitment to returning value to shareholders. Coupled with a strong balance sheet, this financial flexibility allows Lilly to invest aggressively in its pipeline and marketing without jeopardizing liquidity. Moreover, the company’s ability to maintain high margins even as it increases R&D and marketing spend demonstrates effective cost control, which is vital in an industry increasingly beset by pricing headwinds.
Despite impressive growth, Lilly faces a series of mounting pricing headwinds that could materially compress revenue and margin in 2026 and beyond. The company disclosed a 7% decline in average US price for key products, a trend that is projected to continue in the low‑to‑mid‑teens percentage range due to Medicare and Medicaid agreements and direct‑to‑consumer price reductions. The most immediate threat is the mandated price concessions under the Trump‑era “most‑favored‑nation” agreement, which will force Lilly to lower its retail price for obesity therapies in the Medicare population, potentially eroding the higher revenue gains seen in 2025. Furthermore, anticipated Medicaid coverage reductions in key states such as California may reduce overall payer reach for Lilly’s later‑life‑cycle products, compounding the pressure on the company’s earnings.
Lilly’s dominance in the GLP‑1 obesity market is increasingly vulnerable to competitive pressures, both from established rivals and new entrants. Novo Nordisk’s Wegovy pill, already launched in the United States, offers a once‑daily oral formulation that has been rapidly adopted by patients seeking convenience, creating a direct substitute that could erode Lilly’s market share. In addition, the market is now subject to a wave of generic and “compounded” versions, exemplified by Hims & Hers’ low‑price oral copy, which threaten to dilute the perceived value of Lilly’s branded products. The company’s own recent data on Retatrutide also highlights higher discontinuation rates in lower‑BMI patients, raising concerns about long‑term adherence and safety that could dampen adoption.
While Lilly’s existing drugs enjoy robust patent protection until the late 2030s, the company is not immune to the broader industry’s patent‑cliff reality. Products such as Verzenio have already plateaued, and late‑life‑cycle medicines like Trulicity and Talsa are expected to be flat or decline, underscoring the cyclical nature of blockbuster revenue. Additionally, the company’s reliance on a few high‑margin assets makes it vulnerable to unexpected regulatory changes or safety concerns that could accelerate patent expiry or force product withdrawals. The potential influx of biosimilar and generic competition in China and other markets could further compress margins, especially for drugs that have yet to secure robust global reimbursement frameworks.
The breadth of Lilly’s pipeline, while a source of upside, also introduces significant regulatory and execution risk. Orforglipron, Lilly’s first oral weight‑loss drug, is still pending FDA approval, and its commercial launch timing remains uncertain, which could delay the expected volume expansion. Retatrutide’s Phase III data, although promising, revealed discontinuation rates tied to perceived excessive weight loss, a red flag that could impede regulatory acceptance or post‑market adoption. Moreover, the company’s aggressive acquisition strategy—spending billions on assets such as Scribe Therapeutics, Orna Therapeutics, and Innovent Biologics—may dilute management focus and increase integration complexity, potentially hampering the execution of its core pipeline priorities.
Finally, macro‑economic and policy uncertainties loom over Lilly’s growth prospects. Rising inflation and higher interest rates could suppress consumer discretionary spending, directly impacting the direct‑to‑consumer model that Lilly is heavily investing in. Unpredictable policy shifts, especially at the state level regarding Medicaid coverage and reimbursement rates, could alter the payer mix in unforeseen ways. The broader pharmaceutical environment is also experiencing heightened scrutiny over drug pricing and value‑based reimbursement, which may result in tighter pricing controls or accelerated reimbursement denial for newer therapies. Together, these factors could erode both volume and margin, making Lilly’s 2026 guidance an optimistic target amid a highly uncertain landscape.
Despite impressive growth, Lilly faces a series of mounting pricing headwinds that could materially compress revenue and margin in 2026 and beyond. The company disclosed a 7% decline in average US price for key products, a trend that is projected to continue in the low‑to‑mid‑teens percentage range due to Medicare and Medicaid agreements and direct‑to‑consumer price reductions. The most immediate threat is the mandated price concessions under the Trump‑era “most‑favored‑nation” agreement, which will force Lilly to lower its retail price for obesity therapies in the Medicare population, potentially eroding the higher revenue gains seen in 2025. Furthermore, anticipated Medicaid coverage reductions in key states such as California may reduce overall payer reach for Lilly’s later‑life‑cycle products, compounding the pressure on the company’s earnings.
Lilly’s dominance in the GLP‑1 obesity market is increasingly vulnerable to competitive pressures, both from established rivals and new entrants. Novo Nordisk’s Wegovy pill, already launched in the United States, offers a once‑daily oral formulation that has been rapidly adopted by patients seeking convenience, creating a direct substitute that could erode Lilly’s market share. In addition, the market is now subject to a wave of generic and “compounded” versions, exemplified by Hims & Hers’ low‑price oral copy, which threaten to dilute the perceived value of Lilly’s branded products. The company’s own recent data on Retatrutide also highlights higher discontinuation rates in lower‑BMI patients, raising concerns about long‑term adherence and safety that could dampen adoption.
While Lilly’s existing drugs enjoy robust patent protection until the late 2030s, the company is not immune to the broader industry’s patent‑cliff reality. Products such as Verzenio have already plateaued, and late‑life‑cycle medicines like Trulicity and Talsa are expected to be flat or decline, underscoring the cyclical nature of blockbuster revenue. Additionally, the company’s reliance on a few high‑margin assets makes it vulnerable to unexpected regulatory changes or safety concerns that could accelerate patent expiry or force product withdrawals. The potential influx of biosimilar and generic competition in China and other markets could further compress margins, especially for drugs that have yet to secure robust global reimbursement frameworks.
The breadth of Lilly’s pipeline, while a source of upside, also introduces significant regulatory and execution risk. Orforglipron, Lilly’s first oral weight‑loss drug, is still pending FDA approval, and its commercial launch timing remains uncertain, which could delay the expected volume expansion. Retatrutide’s Phase III data, although promising, revealed discontinuation rates tied to perceived excessive weight loss, a red flag that could impede regulatory acceptance or post‑market adoption. Moreover, the company’s aggressive acquisition strategy—spending billions on assets such as Scribe Therapeutics, Orna Therapeutics, and Innovent Biologics—may dilute management focus and increase integration complexity, potentially hampering the execution of its core pipeline priorities.
Finally, macro‑economic and policy uncertainties loom over Lilly’s growth prospects. Rising inflation and higher interest rates could suppress consumer discretionary spending, directly impacting the direct‑to‑consumer model that Lilly is heavily investing in. Unpredictable policy shifts, especially at the state level regarding Medicaid coverage and reimbursement rates, could alter the payer mix in unforeseen ways. The broader pharmaceutical environment is also experiencing heightened scrutiny over drug pricing and value‑based reimbursement, which may result in tighter pricing controls or accelerated reimbursement denial for newer therapies. Together, these factors could erode both volume and margin, making Lilly’s 2026 guidance an optimistic target amid a highly uncertain landscape.